Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis

BACKGROUND/OBJECTIVES: ABP 798 is a proposed biosimilar to the originator biologic rituximab, an anti-CD20 monoclonal antibody. This comparative clinical study evaluated the pharmacokinetics (PK), safety, and efficacy of ABP 798 versus rituximab reference product (RP) in patients with moderate-to-se...

Descripción completa

Detalles Bibliográficos
Autores principales: Burmester, Gerd, Drescher, Edit, Hrycaj, Pawel, Chien, David, Pan, Zhiying, Cohen, Stanley
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567688/
https://www.ncbi.nlm.nih.gov/pubmed/32876780
http://dx.doi.org/10.1007/s10067-020-05305-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567688/
https://www.ncbi.nlm.nih.gov/pubmed/32876780
http://dx.doi.org/10.1007/s10067-020-05305-y

Ejemplares similares